Designing Immunity: Treos Bio’s Data‑Driven Path in Cancer Care
By Olesia Karvetskaia, Business Development Manager
March 18, 2026
In oncology, “personalized medicine” has often been more slogan than standard. Despite breakthroughs in immuno-oncology, many patients with solid tumors still face treatment decisions driven as much by trial-and-error as by data.
Treos Bio is working to change that.
Built around a proprietary AI-enabled platform, Treos designs precision immunotherapies for clearly defined patient populations. Instead of discovering a molecule first and asking later who it might help, Treos starts with population-scale immunogenomic modelling, then engineers candidates predicted to be immunogenic in a large share of the target group. It is an approach that makes drug development look less like chance and more like intentional product design.
Nowhere is this more relevant than in microsatellite-stable metastatic colorectal cancer (MSS mCRC), one of the largest solid tumor indications and historically resistant to many immunotherapies. Treos’ lead program, PolyPEPI1018, is being developed for MSS mCRC patients who have exhausted standard options. Built from multiple carefully selected epitopes engaging both CD4+ and CD8+ T-cells, PolyPEPI1018 aims to pre-qualify patients for a robust, multi-epitope immune response rather than hoping for a responder subset after the fact.
In this video interview filmed during JPM earlier this year, CEO Christopher Gallen explores Treos’ clinical experience and the story behind PolyPEPI1018.
Looking ahead, a key milestone for Treos is the planned Phase 2 OBERTO-202 trial with Charité – Universitätsmedizin Berlin. The study will be conducted as an investigator-led trial at one of Europe’s largest university hospitals.
Beyond the immediate clinical questions in MSS mCRC, OBERTO-202 is designed to test the company’s core hypothesis at scale: that data-driven, population-specific immunotherapy design can translate into more consistent, predictable benefit in real-world oncology settings and lay the groundwork for a broader pipeline of next-generation cancer immunotherapies.